Bank of America’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-282
| Closed | -$360 | – | 8417 |
|
|
2023
Q3 | $360 | Buy |
282
+109
| +63% | +$95 | ﹤0.01% | 7351 |
|
|
2023
Q2 | $57 | Sell |
173
-27
| -14% | -$10 | ﹤0.01% | 7459 |
|
|
2023
Q1 | $86 | Buy |
200
+48
| +32% | +$25 | ﹤0.01% | 7490 |
|
|
2022
Q4 | $81 | Buy |
152
+51
| +50% | +$32 | ﹤0.01% | 7708 |
|
|
2022
Q3 | $0 | Sell |
101
-300
| -75% | -$340 | ﹤0.01% | 8363 |
|
|
2022
Q2 | $0 | Buy |
401
+300
| +297% | +$382 | ﹤0.01% | 8598 |
|
|
2022
Q1 | $0 | Sell |
101
-78
| -44% | -$185 | ﹤0.01% | 8974 |
|
|
2021
Q4 | $0 | Sell |
179
-222
| -55% | -$821 | ﹤0.01% | 8830 |
|
|
2021
Q3 | $2K | Sell |
401
-18
| -4% | -$80 | ﹤0.01% | 7929 |
|
|
2021
Q2 | $2K | Sell |
419
-112
| -21% | -$538 | ﹤0.01% | 7567 |
|
|
2021
Q1 | $3K | Buy |
531
+430
| +426% | +$1.95K | ﹤0.01% | 7212 |
|
|
2020
Q4 | $0 | Hold |
101
| – | – | ﹤0.01% | 7459 |
|
|
2020
Q3 | $0 | Sell |
101
-13,538
| -99% | -$49.7K | ﹤0.01% | 7280 |
|
|
2020
Q2 | $46K | Buy |
13,639
+4,476
| +49% | +$21.2K | ﹤0.01% | 6020 |
|
|
2020
Q1 | $35K | Sell |
9,163
-208,528
| -96% | -$969K | ﹤0.01% | 6000 |
|
|
2019
Q4 | $1.31M | Buy |
217,691
+183,976
| +546% | +$1.26M | ﹤0.01% | 4309 |
|
|
2019
Q3 | $255K | Buy |
33,715
+22,076
| +190% | +$249K | ﹤0.01% | 5514 |
|
|
2019
Q2 | $158K | Buy |
11,639
+11,139
| +2,228% | +$129K | ﹤0.01% | 5765 |
|
|
2019
Q1 | $3K | Buy |
500
+250
| +100% | +$1.22K | ﹤0.01% | 6867 |
|
|
2018
Q4 | $1K | Sell |
250
-542
| -68% | -$2.97K | ﹤0.01% | 7008 |
|
|
2018
Q3 | $6K | Sell |
792
-6,569
| -89% | -$50.4K | ﹤0.01% | 6796 |
|
|
2018
Q2 | $72K | Buy |
7,361
+6,071
| +471% | +$62.2K | ﹤0.01% | 5957 |
|
|
2018
Q1 | $12K | Sell |
1,290
-414
| -24% | -$4.46K | ﹤0.01% | 6565 |
|
|
2017
Q4 | $21K | Sell |
1,704
-3,200
| -65% | -$36.7K | ﹤0.01% | 6404 |
|
|
2017
Q3 | $41K | Buy |
4,904
+4,710
| +2,428% | +$49.8K | ﹤0.01% | 6021 |
|
|
2017
Q2 | $3K | Sell |
194
-4,216
| -96% | -$83.8K | ﹤0.01% | 6695 |
|
|
2017
Q1 | $89K | Buy |
+4,410
| New | +$87.6K | ﹤0.01% | 5672 |
|
|
2016
Q3 | – | Sell |
-1,018
| Closed | -$7K | – | 7431 |
|
|
2016
Q2 | $7K | Buy |
+1,018
| New | +$8.52K | ﹤0.01% | 6608 |
|
|
2016
Q1 | – | Sell |
-83
| Closed | -$1K | – | 7416 |
|
|
2015
Q4 | $1K | Buy |
+83
| New | +$1.1K | ﹤0.01% | 7211 |
|
Bank of America's ZYNE Position: Q4 2023 in Review
Bank of America sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 282 shares — an estimated $360 sold.
Bank of America first reported a position in ZYNE in Q4 2015 and held it in 29 quarters. The position peaked at $1.31M in Q4 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Bank of America reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Bank of America sold 282 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $360.
- Bank of America first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 29 quarters.
- Bank of America's Zynerba Pharmaceuticals, Inc position peaked at $1.31M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.